PD Guide

Biomarkers

A PET scan of a human brainImage copywrite public domainA PET scan of a human brainImage copywrite public domainA biomarker is any characteristic that can be objectively measured and evaluated as an indicator of normal biological processes, pathogenic processes, or pharmacological responses to therapeutic interventions. This may include measures of biochemical components in body fluids and tissues, as well as imaging, physiological, and clinical measures. 

Biomarkers that can be measured with minimally invasive methods are of particular interest for use in clinical trials of therapeutics. They are critical tools for clinical development that can be used for appropriate patient selection, guiding dosing strategies, or as a measure of efficacy.

Types of biomarkers include objective markers that assist in diagnosis, measures of disease progression that change with the disease, or specific measures of drug action. Measurement methods include biochemical examination of tissues and fluids, functional imaging methods, neurophysiological measures of muscle function (Valls-Sole and Valldeoriola, 2002), transcranial ultrasound (Berg et al., 2001; Walter et al., 2002; Mehta et al., 2008; Berg 2006), and assays of olfactory function.

It is important to note that by the time people with Parkinson's disease develop the cardinal motor symptoms, approximately 80% of dopamine neurons have been lost in the nigrostriatal pathway. The identification of biomarkers that track the disease process in this 'pre-motor' stage would allow earlier identification of at-risk individuals.


Reference:
Whitton PS. Inflammation as a causative factor in the aetiology of Parkinson's disease. Br J Pharmacol. 2007;150(8):963-76.
Bartels AL, Willemsen AT, Kortekaas R, de Jong BM, de Vries R, de Klerk O, et al. Decreased blood-brain barrier P-glycoprotein function in the progression of Parkinson's disease, PSP and MSA. Journal of neural transmission (Vienna, Austria : 1996). 2008;115(7):1001-9.
Bartels AL, van Berckel BN, Lubberink M, Luurtsema G, Lammertsma AA, Leenders KL. Blood-brain barrier P-glycoprotein function is not impaired in early Parkinson's disease. Parkinsonism Relat Disord. 2008;14(6):505-8.
Carvey PM, Zhao CH, Hendey B, Lum H, Trachtenberg J, Desai BS, et al. 6-Hydroxydopamine-induced alterations in blood-brain barrier permeability. Eur J Neurosci. 2005;22(5):1158-68.
Westin JE, Lindgren HS, Gardi J, Nyengaard J, Brundin P, Mohapel P, et al. Endothelial proliferation and increased blood-brain barrier permeability in the basal ganglia in a rat model of 3,4-dihydroxyphenyl-L-alanine-induced dyskinesia. J Neurosci. 2006;26(37):9448-61.
Astradsson A, Jenkins BG, Choi JK, Hallett PJ, Levesque MA, McDowell JS, et al. The blood-brain barrier is intact after levodopa-induced dyskinesias in parkinsonian primates--evidence from in vivo neuroimaging studies. Neurobiol Dis. 2009;35(3):348-51.
Rite I, Machado A, Cano J, Venero JL. Blood-brain barrier disruption induces in vivo degeneration of nigral dopaminergic neurons. J Neurochem. 2007;101(6):1567-82.